China Clinical Plan (867.HK, 8A8.SG) NDA for the Improved Original Drug ZUNVEYL for Alzheimer’s Disease Licensed in China

SHENZHEN, CHINA, July 29, 2025 – (ACN Newswire) – China Clinical Plan Holdings Miniature (“CMS” or the “Team”) is ecstatic to insist that on 28 July 2025, the Original Drug Utility (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-covered Capsules) (“ZUNVEYL” or the “Product”) has been authorized by the National Clinical Merchandise Administration of China (NMPA…
Read Extra